Erasca reported preliminary clinical updates for ERAS-0015, its pan-RAS-targeting therapy, after a period of volatility tied to patient-reported and competitive readouts in the RAS space. The company said its pill shrank tumors in 40% of patients with advanced pancreatic cancer and 62% of patients with advanced non–small-cell lung cancer based on data collected in both the U.S. and China. The findings remain preliminary, but the reporting frames them as exceeding expectations and favorable relative to another RAS-targeting drug in the category. Erasca also followed earlier commentary from investors and analysts after a patient death discussion had driven skepticism. For the field, the update is another data point in the rapidly evolving RAS inhibitor landscape where early signals are used to build momentum toward registrational planning.